April 24th 2021
The clinical research director at the UCSF Multiple Sclerosis Center discussed the findings of the long-term open-label assessment of inebilizumab in neuromyelitis optica spectrum disorder.
April 21st 2021
Patients in the randomized controlled trial and the open-label extension treated with inebilizumab experienced similar rates of being attack-free, extending as far as 4 years.
March 22nd 2021
The findings were consistent with the established safety profile for eculizumab in other non-neurologic indications, according to study authors.
